Tofacitinib for Steroid-Resistant Thyroid Eye Disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with Graves' orbitopathy (thyroid-related eye disease) with moderate-to-severe symptoms affecting daily activities
- Active disease with a Clinical Activity Score of 3 or higher, AND have either failed high-dose steroids (at least 3 grams of IV methylprednisolone) or cannot safely take steroids due to other health conditions
- Thyroid function is controlled or stable on medication for at least 4 weeks before entering the study
- Women of childbearing age must use effective birth control during and for 4 weeks after the study
- No sight-threatening complications, recent eye surgery, or use of certain other biologic drugs in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This trial tests whether atorvastatin, a cholesterol-lowering drug, can improve symptoms of thyroid eye disease (Graves' orbitopathy). It is for people with moderate-to-severe, active eye disease who have not recently used steroids or other treatments for it.
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
This trial tests a new medicine called MHB018A for people with active thyroid eye disease (TED), a condition that causes the eyes to bulge and become inflamed. The study aims to see if the drug can reduce symptoms and improve eye appearance compared to a placebo.
This trial tests whether atorvastatin, a common cholesterol medicine, can reduce inflammation and improve eye symptoms in people with moderate-to-severe thyroid eye disease. It may help by calming the immune response that causes the eye problems.
This trial tests a new medication for people with long-term thyroid eye disease that has lasted over a year. The aim is to see if it can reduce symptoms like bulging and discomfort.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.